Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy

被引:47
作者
Eger, Katrien [1 ]
Hashimoto, Simone [1 ]
Braunstahl, Gert Jan [2 ]
ten Brinke, Anneke [3 ]
Patberg, Kornelis W. [4 ]
Beukert, Annelies [5 ]
Smeenk, Frank [6 ]
van der Sar-van der Brugge, Simone [7 ]
Weersink, Els J. M. [1 ]
Bel, Elisabeth H. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Resp Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Franciscus Gasthuis & Vlietland, Dept Pulmonol, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands
[3] Med Ctr Leeuwarden, Dept Pulmonol, Henri Dunantweg 2, NL-8934 AD Leeuwarden, Netherlands
[4] Isala Klin, Dept Pulmonol, Dokter van Heesweg 2, NL-8025 AB Zwolle, Netherlands
[5] Martini Ziekenhuis, Dept Pulmonol, Van Swietenpl 1, NL-9728 NT Groningen, Netherlands
[6] Catharina Hosp, Dept Pulmon, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands
[7] Amphia Hosp, Dept Resp Med, Molengracht 21, NL-4818 CK Breda, Netherlands
关键词
Biologics; COVID-19; SARS-CoV-2; Severe asthma; COVID-19;
D O I
10.1016/j.rmed.2020.106287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It is unclear whether asthma and asthma medications increase or decrease the risk of severe COVID-19, and this is particularly true for patients with severe asthma receiving biologics. Objectives: The aim of this study was to assess incidence and disease course of COVID-19 in patients with severe asthma on biologic therapy (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab), as compared with COVID-19 data from the general Dutch population. Methods: COVID-19 cases were identified through a prospective ongoing survey between March 17 and April 30, 2020 among all severe asthma specialists from 15 hospitals of the Dutch Severe Asthma Registry RAPSODI. From these cases, data was collected on patient characteristics, including co-morbidities, COVID-19 disease progression and asthma exacerbations. Findings were then compared with COVID-19 data from the general Dutch population. Results: Of 634 severe asthma patients who received biologic therapy in RAPSODI, 9 (1.4%) were diagnosed with COVID-19. Seven patients (1.1%) required hospitalization for oxygen therapy, of which 5 were admitted to the intensive care for intubation and mechanical ventilation. One patient died (0.16%). All intubated patients had >= 1 co-morbidities. Odds (95%CI) for COVID-19 related hospitalization and intubations were 14 (6.6-29.5) and 41 (16.9-98.5) times higher, respectively, compared to the Dutch population. One patient presented with an asthma exacerbation. Conclusion: Patients with severe asthma using biologic therapy showed to have a more severe course of COVID-19 compared to the general population. This may be due to co-morbidities, the severity of asthmatic airway inflammation, the use of biologics, or a combination of these.
引用
收藏
页数:5
相关论文
共 38 条
  • [1] [Anonymous], 2020, Overview of Motor Vehicle Crashes in 2019, P1
  • [2] Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry
    Antonicelli, Leonardo
    Tontini, Chiara
    Manzotti, Giuseppina
    Ronchi, Luca
    Vaghi, Adriano
    Bini, Francesco
    Scartabellati, Alessandro
    Menzella, Francesco
    De Michele, Fausto
    Musarra, Antonino
    Micheletto, Claudio
    Bilo, Maria Beatrice
    [J]. ALLERGY, 2021, 76 (03) : 902 - 905
  • [3] Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation
    Beurnier, Antoine
    Jutant, Etienne-Marie
    Jevnikar, Mitja
    Boucly, Athenais
    Pichon, Jeremie
    Preda, Mariana
    Frank, Marie
    Laurent, Jeremy
    Richard, Christian
    Monnet, Xavier
    Duranteau, Jacques
    Harrois, Anatole
    Chaumais, Marie-Camille
    Bellin, Marie-France
    Noel, Nicolas
    Bulifon, Sophie
    Jais, Xavier
    Parent, Florence
    Seferian, Andrei
    Savale, Laurent
    Sitbon, Olivier
    Montani, David
    Humbert, Marc
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (05)
  • [4] ACE2, TMPRSS2, andfuringeneexpression in the airways of people with asthma-implications for COVID-19
    Bradding, Peter
    Richardson, Matthew
    Hinks, Timothy S. C.
    Howarth, Peter H.
    Choy, David F.
    Arron, Joseph R.
    Wenzel, Sally E.
    Siddiqui, Salman
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (01) : 208 - +
  • [5] Broadhurst R, 2020, ANN AM THORAC SOC, V17, P1645, DOI 10.1513/AnnalsATS.202006-613RL
  • [6] Carli G., 2020, CARLI ALLERGY 2020 I, DOI [10.1111/all.14426, DOI 10.1111/ALL.14426]
  • [7] The relationship between human coronaviruses, asthma and allergy-An unresolved dilemma
    Chalubinski, Maciej
    Gajewski, Adrian
    Kowalski, Marek L.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2020, 50 (10) : 1122 - 1126
  • [8] Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19
    Chhiba, Krishan D.
    Patel, Gayatri B.
    Vu, Thanh Huyen T.
    Chen, Michael M.
    Guo, Amina
    Kudlaty, Elizabeth
    Mai, Quan
    Yeh, Chen
    Muhammad, Lutfiyya N.
    Harris, Kathleen E.
    Bochner, Bruce S.
    Grammer, Leslie C.
    Greenberger, Paul A.
    Kalhan, Ravi
    Kuang, Fei Li
    Saltoun, Carol A.
    Schleimer, Robert P.
    Stevens, Whitney W.
    Peters, Anju T.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (02) : 307 - +
  • [9] Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean Disease Control and Prevention
    Choi, Hyo-Geun
    Wee, Jee Hye
    Kim, So Young
    Kim, Joo-Hee
    Kim, Hwan, I
    Park, Ji-Young
    Park, Sunghoon
    Hwang, Yong, I
    Jang, Seung Hun
    Jung, Ki-Suck
    [J]. ALLERGY, 2021, 76 (03) : 921 - 924
  • [10] Effect of asthma and asthma medication on the prognosis of patients with COVID-19
    Choi, Yong Jun
    Park, Ju-Young
    Lee, Hye Sun
    Suh, Jin
    Song, Jeung Yoon
    Byun, Min Kwang
    Cho, Jae Hwa
    Kim, Hyung Jung
    Lee, Jae-Hyun
    Park, Jung-Won
    Park, Hye Jung
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 57 (03)